However, the largest meta-analysis of randomized controlled trials (RCTs) in individuals with T2DM suggested little difference in prostate cancer incidence between users of SGLT2 inhibitors and users of placebo or active comparators.10 Here, SLC5A2 is linked to type 2 diabetes mellitus.